Anti-flavivirus compounds and methods of use
US-11471443-B2 · Oct 18, 2022 · US
Method for inhibiting dengue virus infection
US11779570B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11779570-B2 |
| Application number | US-202217809345-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 28, 2022 |
| Priority date | Dec 19, 2018 |
| Publication date | Oct 10, 2023 |
| Grant date | Oct 10, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.
First claim
Opening claim text (preview).
We claim: 1. A method for inhibiting dengue virus infection in human or non-human mammalian cells in vitro or in vivo, said method comprising contacting a compound to a human or non-human mammalian cell in vitro or in vivo after exposure of the cell to the dengue virus, wherein the compound has the following chemical structure: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein said contacting is in vitro. 3. The method of claim 1 , wherein said contacting is in vivo. 4. The method of claim 1 , wherein the cell is a human cell. 5. The method of claim 1 , wherein the cell is a non-human mammalian cell.
Assignees
Inventors
Classifications
- A61K31/4184Primary
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title
Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60) · CPC title
having three-membered rings, e.g. oxirane, fumagillin · CPC title
condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11779570B2 cover?
- The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a su…
- Who is the assignee on this patent?
- Univ Florida State Res Found, Us Health, Univ Pennsylvania
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4184. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).